Literature DB >> 3733277

Nifedipine serum concentrations following sublingual and oral doses.

G R Brown, D G Fraser, J A Castile, P Gaudreault, D R Platt, P A Friedman.   

Abstract

Although nifedipine is commonly administered sublingually in the clinical setting, a comparison of the serum concentrations obtained by this route vs oral administration has not been previously made. Nifedipine serum concentrations were measured in 6 healthy subjects following sublingual or oral administration of one nifedipine 10 mg capsule. Serum nifedipine concentrations were measured at regular intervals and demonstrated that sublingual administration produced measurable nifedipine concentrations sooner than oral administration. Peak nifedipine serum concentrations were less following sublingual administration (41.9 +/- 24.9 ng/ml) than following oral administration (99.6 +/- 49.8 ng/ml, p less than 0.05). The time to peak nifedipine serum concentration was also longer following sublingual administration than with the oral dose (74 +/- 24 minutes vs 40 +/- 14 minutes, p less than 0.05). Despite these differences, the areas under the serum concentration-time curve of the two routes of administration were similar. These differences in nifedipine concentrations may be an important consideration when choosing the route of administration of nifedipine.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3733277

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  5 in total

1.  Radionuclide monitoring of left ventricular function after sublingual nifedipine administration at rest and during moderate physical activity.

Authors:  A Ferro; M Salvatore; A Cuocolo
Journal:  J Nucl Cardiol       Date:  2001 Nov-Dec       Impact factor: 5.952

2.  Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs.

Authors:  Edward Perez-Reyes; Amy L Van Deusen; Iuliia Vitko
Journal:  J Pharmacol Exp Ther       Date:  2008-10-30       Impact factor: 4.030

3.  Usefulness of targeting lymphocyte Kv1.3-channels in the treatment of respiratory diseases.

Authors:  Itsuro Kazama; Tsutomu Tamada; Masahiro Tachi
Journal:  Inflamm Res       Date:  2015-07-24       Impact factor: 4.575

4.  Non-bioequivalence of sublingual nifedipine.

Authors:  N Rietbrock; M Kausch; M Engelhardt; B G Woodcock
Journal:  Br J Clin Pharmacol       Date:  1987-05       Impact factor: 4.335

5.  Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor.

Authors:  Chia-Wen Hsu; Jinghua Zhao; Ruili Huang; Jui-Hua Hsieh; Jon Hamm; Xiaoqing Chang; Keith Houck; Menghang Xia
Journal:  Sci Rep       Date:  2014-09-26       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.